Koko

radiation oncologist, head of department, Acibadem Tokuda hospital,Sofia ,head and neck cancer , GI cancer , SBRT,

[Jose Fernando Moura, PhD @FernandoOnco]

The gap between these Kaplan-Meier curves is so thin, even my ophthalmologist would ask for a second opinion!😂 @myESMO @BalazsHalmosMD #ESMO26

[Erman Akkus @Erman_Akkus]

🔴Do we really need frequent CT-scans after curative resection of CRC❓
PRODIGE-13 @Annals_Oncology

❌No OS benefit at 5th year
✅US/3m and thoracic radiography/6m +CEA may be enough

👉https://t.co/pmx60J0PzQ

@myESMO #cancer #oncology #MedX #colorectal #GI @OncoAlert @realbowtiedoc

[giuseppe Minniti @gminniti2012]

Another dogma is disappearing: SRS is effective for SCLC BM.
Stereotactic Radiosurgery in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases: A Multi-Institutional, Phase II, Prospective Clinical Trial | Journal of Clinical Oncology https://t.co/D08loaWWb3

[ESTRO @ESTRO_RT]

Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy, published in @NEJM.
👉Read it before your patients: https://t.co/bi8p96p5rW

[Drew Moghanaki @DrewMoghanaki]

🫁 SBRT has forever changed lung cancer treatment. With sub-millimeter accuracy, we now treat and even cure lung cancer in a single session. There is zero downtime with this treatment as there’s no need for anesthesia or even lidocaine. It’s just amazing. #radonc https://t.co/VSWqrv3dDX

[Gustavo @gusviani]

🎙 Randomized Trial 🚨: SBRT vs. RFA for Recurrent Small HCC—Is It Time to Rethink Local Treatment? @OncoAlert

🔬 Study Highlights:
📌 Phase III trial, 166 👥 with recurrent HCC (≤5 cm, single lesion).
📌 Randomized to RFA (n=83) or SBRT (n=83)

Key Outcomes:
✅ Local progression-free survival (LPFS):
•2-year LPFS: 92.7% (SBRT)🏆 vs. 75.8% (RFA) (HR: 0.45, p=0.014).

✅ Progression-free survival (PFS):
•Median PFS: 37.6 months (SBRT) vs. 27.6 months (RFA) (p=0.19).👌

✅ Overall survival (OS):
•2-year OS: 97.6% (SBRT) vs. 93.9% (RFA) (p=0.83).👌

✅ Safety: Comparable acute and late adverse events.👍

📣 Implications for Practice:
SBRT demonstrated ⬆️ local control while maintaining similar safety and OS compared to RFA.

[Gustavo @gusviani]

🎙 Concurrent 🫁☢️ ⬆️ the PFS and OS w/ acceptable and tolerable toxicity in 👥 w/ #EGFR-mutated oligo-organ metastatic #NSCLC‼️ @OncoAlert

🎯 OBJECTIVE
•Compare first-line 🫁☢️ (TRT) with #EGFR-TKIs VS. to EGFR-TKIs alone in 👥 w/ EGFR-mutated oligo-organ metastatic #NSCLC

🔬METHODS :
• Ph III trial, 118 👥 enrolled
•👥 in the TKI + 🫁☢️group ➡️ 60 Gy ☢️ to primary tumors and ➕ regional lymph nodes
•PFS 🥇endpoint, w/ OS and adverse events 🥈 endpoints

📊RESULTS:
•The TKI + 🫁☢️ group had significantly better outcomes:
•⬆️PFS: 17 vs 10.6 m 🦾
•⬆️OS: 34.4 vs 26.2m 🦾
•⬆️ local control but ⬆️ AEs (11.9% vs 5.1%)🤔

https://t.co/Kimi6DKqDb

[Nicholas van As @nickva1]

Delighted to share the results of #PACE B trial, published in @NEJM today
5 fraction SBRT is non inferior to CRT!
https://t.co/9ja6OZFRab
@alison_tree @ICR_CTSU @EmmaHall71 @royalmarsdenNHS @DrAndrewLoblaw @cpeedell @DrTolan @ProfJOSullivan @DrSuneil_PCa

[Andrea Lancia @dr_lancia]

🇬🇧PACE A, ph 3, SBRT vs RP randomized toxicity data

⬇️ urinary incontinence
⬇️impaired sexual function
⬆️ mild GI symptoms
➡️Every Prostate Cancer patient MUST see a Rad Onc immediately after diagnosis (NOT questionable anymore)

kudos to the authors!

https://t.co/KPFA7z9h7k

[NEJM @NEJM]

Presented at #ESMO24:

Among patients with limited-stage small-cell lung cancer, overall and progression-free survival were significantly longer with durvalumab adjuvant therapy added to standard concurrent chemoradiotherapy. Full ADRIATIC trial results: https://t.co/G6gpxMMCkV

[Albert Koong, MD PhD @ACKoongMDPhD]

Congrats @ebludmir and @ChadTangMD! This @MDAndersonNews P2 randomized study shows PFS of 10.3 mo vs. 2.5 mo in #PancreasCancer pts with oligometastatic dz treated with metastasis-directed therapy+sys tx vs. sys tx alone. #radonc #endcancer https://t.co/LlyGthsSSt

[Erman Akkus @Erman_Akkus]

📢Addition of local therapy (RT) in oligometastatic (≤5) pancreatic cancer
EXTEND trial @JCO_ASCO

✅mPFS: 10.3 mo vs. 2.5 mo
HR: 0.43 (95% CI, 0.20 to 0.94), p=0.030
⁉���Systemic immune activation
❌No OS difference

👉https://t.co/wDvPBgJYrP

@ASCO @JCOOP_ASCO @P_C_E_ @PanCAN @5_utr @OncoAlert #cancer #oncology #MedX

[Jennifer A. Marks, MD @jennifermarksmd]

Feels way more complicated than this (esp with TKI/sequencing) but a 2024 #NSCLC management algorithm for boards
#lcsm #MedTwitter #OncTwitter

[Corinne Faivre-Finn @finn_corinne]

🔥 off the press @JTOonline - @EORTC LungTech trial 8×7.5Gy in central NSCLC
At 3-year
▶️freedom from local progression 81.5%
▶️distant progression 29.8%
▶️SBRT-related acute and late AEs ≥ G3 in 6.5% and 19.4 %
https://t.co/PMb6y5Qhdc

[Filippo Alongi @alongi_filippo]

Treat with RX bone Mets not only in case of symptoms.

-RT delivered prophylactically to asymptomatic,high-risk bone metastases reduced SRE and hospitalizations.

⬆️ in OS with prophylactic RT was also found.

Another important message to change practice
https://t.co/SnK586GCHr

[Radiotherapy & Oncology @RO_GreenJournal]

New article (Vol 190)

RT to reinvigorate immunotherapy activity after acquired resistance in metastatic non-small-cell lung cancer: A pooled analysis of two institutions prospective phase II single arm trials
Ilinca Popp et al.

https://t.co/M72T0LysdW

https://t.co/9hxYOYZGIY

[Alison Tree 💙 @alison_tree]

Great talk by @Mat_Guc at the Turkish UROK conference. Always shocking to be reminded how little of the global cancer research spend goes on the treatments that cure most patients. Imagine what radonc could achieve with a level playing field #radonc

[George W Sledge MD @GeorgeSledge51]

Monarch 3 frontline OS results for Abema continue to show numerically impressive improvements but a significant p value remains frustratingly elusive. This is confusing given positive second line and adjuvant results.

[Dr Amol Akhade @SuyogCancer]

So abemaciclib fails to give OS benifit even after 8 years. Monarch3 . Final OS Data. Only 32 % got subsequent CDk inhibitors in control arm . Still no OS. Intresting. @ErikaHamilton9 @SABCSSanAntonio #SABCS23 @OncoAlert

[Icro Meattini @Icro_Meattini]

A giant of radiation oncology!
High quality data presented #SABCS23 today

Primary outcome of NRG/NSABP B-51 trial #breastcancer

@AACR @SABCSSanAntonio @NRGonc @UTHealthSAMDA @OncoAlert